Posted by Jedi on January 17, 2008, at 2:25:29
In reply to Re: what drugs would kill off my remaining emotion » Justherself54, posted by CareBear04 on January 17, 2008, at 0:00:16
> i'm not on any antidepressants currently because they have tended to make me manic in the past. I'm on lithium and lamictal, which seemed to be working decently before, but not so much in the past week or so.
> thanks,
> cb
Hi cb,
Have you tried the atypical antipsychotics for your bipolar disorder?
JediReference:
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.Perlis RH.
Harvard Medical School, 15 Parkman St, AC 812, Boston, MA 02114-3117, USA. rperlis@partners.orgManagement of bipolar disorder (BPD) may require multiple medications, including lithium, anticonvulsants, and antipsychotics (both conventional and atypical). Updated treatment guidelines reflect an expanded role for atypical antipsychotics (AAPs) in BPD treatment. Five AAPs--olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole--are approved by the US Food and Drug Administration (FDA) as monotherapy for first-line treatment of acute manic and (except for quetiapine) mixed episodes. Two AAPs--olanzapine (in fixed-dose combination with fluoxetine) and quetiapine--are also FDA approved for bipolar depression. For long-term maintenance therapy, one option is to continue effective, well-tolerated acute phase treatment; however, only olanzapine and aripiprazole are FDA approved for maintenance, based on evidence from randomized, placebo-controlled clinical trials. Although head-to-head comparisons are scarce, meta-analysis data suggest that olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole have similar antimanic efficacy; therefore, AAP selection for this indication should be guided by other considerations such as safety, tolerability, and cost. Safety and tolerability issues to consider when selecting an AAP include metabolic dysfunction (weight gain, type 2 diabetes, and dyslipidemia); hyperprolactinemia; extrapyramidal symptoms; QTc prolongation; and pharmacokinetic drug interactions.
PMID: 18041879 [PubMed - indexed for MEDLINE]
poster:Jedi
thread:807143
URL: http://www.dr-bob.org/babble/20080114/msgs/807165.html